Dr. Jeff Geschwind Director of Oncology at USA Clinics Group and Medical Director of Oncology and Image-Guided Therapy at NAMSA to speak at the GEST meeting in New York City May 18, 2023.
Dr. Jeff Geschwind, the Director of Oncology at USA Clinics Group, the largest office-based labs practice in the United States and Director of Oncology and Image-Guided Therapy at NAMSA will be speaking at the upcoming GEST meeting in New York City. Dr. Geschwind is an internationally known interventional radiologist and researcher with recognized expertise in the field of liver cancer. He has pioneered several new techniques to treat patients with liver cancer and his research has established the use of cone-beam CT (CBCT) as the standard of care for all intra arterial therapies for liver cancer.
Dr. Geschwind is also known for research into the molecular mechanisms of liver cancer and for his work in developing new imaging techniques to help diagnose and monitor liver cancer. He has published nearly 300 research manuscripts and has received many awards and honors for his contributions to the field of interventional radiology and oncology.
Dr. Geschwind was an invited visiting professor at many prestigious institutions throughout the world and he was the Principal Investigator or Co-PI on more than 40 clinical trials, most investigator initiated and some care changing trials.
He is currently the Director of Oncology at USA Clinics Group where he is responsible for the development of specialized centers dedicated to the care of cancer patients using minimally invasive image –guided procedures, known as interventional oncology procedures. He has devoted the last decade of his career to the development of Interventional Oncology both as a professor at Johns Hopkins University and at Yale School of Medicine during his tenure as Chairman of the Department of Radiology and Biomedical Imaging.
Dr. Geschwind is considered a pioneer and father of the field of Interventional Oncology, now considered the fourth pillar of oncology (along with medical, surgical and radiation), and founded the World Conference on Interventional Oncology in 2005, which is now the official meeting of the newly formed Society of Interventional Oncology, for which he served as its first President. These outpatient Interventional Oncology Centers will contribute to improving the lives of thousands of cancer patients and provide such patients access to cutting edge Interventional Oncology procedures, provided in an outpatient setting, thereby decreasing costs dramatically.
Dr. Geschwind’s lecture at the upcoming GEST meeting in New York will address the latest developments in liver cancer.
For more, visit https://jeffgeschwind.com
GEST meeting in New York City May 18, 2023 https://annual.thegestgroup.com/GEST23/Public/Enter.aspx
Media Contact
Contact Person: Jeff Geschwind
Email: Send Email
Phone: +1 410 446 8071
Country: United States
Website: www.jeffgeschwind.com
